Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice

Cancer Research

Volumn 63, Issue 6, 2003, Pages 1270-1279

  Blaskovich, Michelle A ^a,b   Sun, Jiazhi ^a,b   Cantor, Alan ^a   Turkson, James ^a,b   Jove, Richard ^a,b   Sebti, Saïd M ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CUCURBITACIN I; JSI 124; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHOTYROSINE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENESIS; CELL STRAIN 3T3; CELL SURVIVAL; CELL TRANSFORMATION; CONTROLLED STUDY; DNA BINDING; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IC 50; IMMUNOCOMPETENCE; LUNG ADENOCARCINOMA; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SERUM RESPONSIVE ELEMENT; SIGNAL TRANSDUCTION;

3T3 CELLS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; DNA-BINDING PROTEINS; HUMANS; JANUS KINASE 2; MAP KINASE SIGNALING SYSTEM; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, NUDE; PHOSPHORYLATION; PHOSPHOTYROSINE; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TRITERPENES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037444373     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Stark, G. R., Kerr, I. M., Williams, B. R., Silverman, R. H., and Schreiber, R. D. How cells respond to interferons. Annu. Rev. Biochem., 67: 227-264, 1998.
2. Horvath, C. M., and Damell, J. E. The state of the STATs: recent developments in the study of signal transduction to the nucleus. Curr. Opin. Cell Biol., 9: 233-239, 1997.
3. Ihle, J. N., and Kerr, I. M. JAKs and STATs in signaling by the cytokine receptor superfamily. Trends Genet., 11: 69-74, 1995.
4. Schindler, C., and Darnell, J. E., Jr. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu. Rev. Biochem., 64: 621-651, 1995.
5. Ihle, J. N., Witthuhn, B. A., Quelle, F. W., Yamamoto, K., and Silvennoinen, O. Signaling through the hematopoietic cytokine receptors. Annu. Rev. Immunol., 13: 369-398, 1995.
6. Leaman, D. W., Leung. S., Li, X., and Stark, G. R. Regulation of STAT-dependent pathways by growth factors and cytokines. FASEB J., 10: 1578-1588, 1996.
7. Schaper, F., Gendo, C., Eck, M., Schmitz, J., Grimm, C., Anhuf, D., Kerr, I. M., and Heinrich, P. C. Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase JAK1 and limits acute-phase protein expression. Biochem. J., 335: 557-565, 1998.
8. Stofega, M. R., Wang, H., Ullrich, A., and Carter-Su, C. Growth hormone regulation of SIRP and SHP-2 tyrosyl phosphorylation and association. J. Biol. Chem., 273: 7112-7117, 1998.
9. Yu, C. L., Jin, Y. J., and Burakoff, S. J. Cytosolic tyrosine dephosphorylation of STAT5. Potential role of SHP-2 in STAT5 regulation. J. Biol. Chem., 275: 599-604, 2000.
10. Seidel, H. M., Milocco, L. H., Lamb, P., Darnell, J. E., Jr., Stein, R. B., and Rosen, J. Spacing of palindromic half sites as a determinant of selective STAT (signal transducers and activators of transcription) DNA binding and transcriptional activity. Proc. Natl. Acad. Sci. USA, 92: 3041-3045. 1995.
11. Turkson, J., Bowman, T., Adnane, J., Zhang, Y., Djeu, J. Y., Sekharam, M., Frank, D. A., Holzman, L. B., Wu, J., Sebti, S., and Jove, R. Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in STAT3 transcriptional activity induced by the Src oncoprotein. Mol. Cell. Biol., 19: 7519-7528, 1999.
12. Bowman, T., Yu, H., Sebti, S., Dalton, W., and Jove, R. Signal transducers and activators of transcription: novel targets for anticancer therapeutics. Cancer Control, 6: 427-435, 1999.
13. Turkson, J., and Jove, R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene, 19: 6613-6626, 2000.
14. Bowman, T., Garcia, R., Turkson. J., and Jove, R. STATs in oncogenesis. Oncogene, 19: 2474-2488, 2000.
15. Yu, C. L., Meyer, D. J., Campbell, G. S., Larner, A. C., Carter-Su, C., Schwartz, J., and Jove, R. Enhanced DNA-binding activity of a STAT3-related protein in cells transformed by the Src oncoprotein. Science (Wash. DC), 269: 81-83, 1995.
16. Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao. Y., Pestell, R. G., Albanese, C., and Darnell, J. E., Jr. STAT3 as an oncogene. Cell, 98: 295-303, 1999.
17. Niu, G., Heller, R., Catlett-Falcone, R., Coppola, D., Jaroszeski, M., Dalton, W., Jove, R., and Yu, H. Gene therapy with dominant-negative STAT3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res., 59: 5059-5063, 1999.
18. Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernandez-Luna, J. L., Nunez, G., Dalton, W. S., and Jove, R. Constitutive activation of STAT3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity, 10: 105-115, 1999.
19. Lemer. E. C., Qian, Y., Blaskovich, M. A., Fossum, R. D., Vogt, A., Sun, J., Cox, A. D., Der, C. J., Hamilton, A. D., and Sebti, S. M. Ras CAAX peptidomimetic FT1-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J. Biol. Chem., 270: 26802-26806, 1995.
20. Stockwell, B. R., Haggarty, S. J., and Schreiber, S. L. High-throughput screening of small molecules in miniaturized mammalian cell-based assays involving posttranslational modifications. Chem. Biol., 6. 71-83. 1999.
21. Blaskovich, M. A., Lin, Q., Delarue, F. L., Sun, J., Park, H. S., Coppola, D., Hamilton, A. D., and Sebti, S. M. Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice. Nat. Biotechnol., 18: 1065-1070, 2000.
22. Zhang, D., Sun, M., Samols, D., and Kushner, I. STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6. J. Biol. Chem., 271: 9503-9509, 1996.
23. Yamauchi, K., Holt, K., and Pessin, J. E. Phosphatidylinositol 3-kinase functions upstream of Ras and Raf in mediating insulin stimulation of c-fos transcription. J. Biol. Chem., 268: 14597-14600, 1993.
24. Turkson, J., Ryan, D., Kim, J. S., Zhang, Y., Chen, Z., Haura, E., Laudano, A., Sebti, S., Hamilton, A. D., and Jove, R. Phosphotyrosyl peptides block STAT3-mediated DNA-binding activity, gene regulation, and cell transformation. J. Biol. Chem., 276: 45443-45455, 2001.
25. Sun, J., Blaskovich, M. A., Knowles, D., Qian, Y., Ohkanda, J., Bailey, R. D., Hamilton, A. D., and Sebti, S. M. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. Cancer Res., 59: 4919-4926, 1999.
26. Witkowski, A., and Konopa, J. Binding of the cytotoxic and antitumor triterpenes, cucurbitacins, to glucocorticoid receptors of HeLa cells. Biochim. Biophys. Acta, 674: 246-255, 1981.
27. Duncan, K. L., Duncan, M. D., Alley, M. C., and Sausville, E. A. Cucurbitacin E-induced disruption of the actin and vimentin cytoskeleton in prostate carcinoma cells. Biochem. Pharmacol., 52: 1553-1560, 1996.
28. Dinan, L., Whiting, P., Girault, J. P., Lafont, R., Dhadialla, T. S., Cress, D, E., Mugat, B., Antoniewski, C., and Lepesant, J. A. Cucurbitacins are insect steroid hormone antagonists acting at the ecdysteroid receptor. Biochem. J., 327: 643-650, 1997.
29. Sebti, S. New drug targets and therapies for cancer. Oncog. Rev., 19: 6549-6692, 2000.
30. Witkowski, A., Woynarowska. B., and Konopa, J. Inhibition of the biosynthesis of deoxyribonucleic acid, ribonucleic acid, and protein in HeLa S3 cells by cucurbitacins, glucocorticoid-like cytotoxic triterpenes. Biochem. Pharmacol., 33: 995-1004, 1984.
31. Duncan, M. D., and Duncan, K. L. Cucurbitacin E targets proliferating endothelia. J. Surg. Res., 69: 55-60, 1997.
32. Smit, H. F., van den Berg, A. J., Kroes, B. H., Beukelman, C. J., Quarles van Ufford, H. C., van Dijk, H., and Labadie, R. P. Inhibition of T-lymphocyte proliferation by cucurbitacins from Picrorhiza scrophulariaeflora. J. Nat. Prod. (Lloydia), 63: 1300-1302, 2000.
33. Konoshima, T., Takasaki, M., Kozuka, M., Nagao, T., Okabe, H., Irino, N., Nakasumi, T., Tokuda, H., and Nishino, H. Inhibitory effects of cucurbitane triterpenoids on Epstein-Barr virus activation and two-stage carcinogenesis of skin tumor. II. Biol. Pharm. Bull., 18: 284-287, 1995.
34. Musza, L. L., Speight, P., McElhiney, S., Barrow, C. J., Gillum, A. M., Cooper, R., and Killar, L. M. Cucurbitacins, cell adhesion inhibitors from Conobea scoparioides. J. Nat. Prod. (Lloydia), 57: 1498-1502, 1994.